Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas-Reference-Cited by-同舟云学术

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

Published:2013-10-07 Issue:2 Volume:120 Page:222-228
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ahmadi Tahamtan¹,Chong Elise A.¹,Gordon Amanda¹,Aqui Nicole A.¹,Nasta Sunita D.¹,Svoboda Jakub¹,Mato Anthony R.²,Schuster Stephen J.¹

Affiliation:

1. Lymphoma Program; Abramson Cancer Center of the University of Pennsylvania; Philadelphia Pennsylvania

2. Chronic Lymphocytic Leukemia Program, John Theurer Cancer Center; Hackensack University Medical Center; Hackensack New Jersey

Funder

Celgene corporation

Leukemia and Lymphoma Society

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference24 articles.

1. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005

2. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study;Hochster;J Clin Oncol,2009

3. The impact of rituximab resistance on overall survival rate in low-grade follicular lymphoma [abstract];Abdollahi;Blood (ASH Annual Meeting Abstracts),2008

4. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo;Reddy;Br J Haematol,2008

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. „Patient-reported outcomes“ in medizinischen Registern;Die Onkologie;2024-03-01

2. Immune-based therapies in diffuse large B-cell lymphoma;Expert Opinion on Investigational Drugs;2023-06-03

3. Targeted immunotherapies to consider for B Cell non-hodgkin lymphoma;Expert Review of Precision Medicine and Drug Development;2021-08-30

4. Marginal Zone Lymphomas;The Cancer Journal;2020-07

5. Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine;Cancer Immunology, Immunotherapy;2019-10-16